InduPro Raises $77M Series B to Advance Cancer Drug IDP-001

The round also saw participation from existing investors Vida Ventures, MRL Ventures Fund, Emerson Collective and Euclidean Capital, along with new investors Solasta Ventures, Sanofi and Eli Lilly and Company.

The company will use the fresh capital to:

• Advance Phase 1 clinical development of IDP-001
• Generate early proof-of-concept clinical data
• Expand its broader preclinical pipeline
• Develop new therapies targeting cancer and autoimmune diseases

InduPro also announced that the first patient has been dosed in the Phase 1 clinical trial of IDP-001.

Funding Snapshot

About InduPro

Founded to develop next-generation therapeutics, InduPro uses protein proximity biology to identify new therapeutic targets for cancer and autoimmune diseases.

Its technology maps the spatial organization of proteins on cell surfaces to discover novel co-target pairs that could improve the selectivity and effectiveness of treatments.

Core offerings include:

• Bispecific antibodies
• Antibody-drug conjugates (ADCs)
• T-cell engagers (TCEs)
• Novel tumor-selective proximity antigens

IDP-001: Lead Oncology Program

IDP-001 is a potential first-in-class proximity-based bispecific ADC designed to target EGFR and TAPA-E1, a novel tumor-associated proximity antigen.

The Phase 1 trial is evaluating the drug's safety, tolerability, pharmacokinetics and early antitumor activity in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and other squamous solid tumors.

Leadership Comments

“We are delighted to have the support of this outstanding group of life sciences investors and strategic partners who recognize the potential of our proximity-guided platform to create precision therapeutics in oncology and autoimmune disease,” said Prakash Raman, Ph.D., Chief Executive Officer of InduPro. “With IDP-001 now in the clinic, our focus is on disciplined clinical execution. I am pleased with how effectively our team has advanced the program and encouraged by the strong early interest from principal investigators and clinical sites as we expand the study.”

“Treatment options for squamous cancers have not kept pace with advances in other solid tumors,” said Amanda J. Redig, M.D., Ph.D., Chief Medical Officer of InduPro. “IDP-001 was designed to help address this gap by harnessing the power of biological proximity. The targets for our bispecific ADC were selected based not only on their shared biology across squamous tumors, but also on their proximity on the surface of cancer cells, a spatial relationship not found in normal tissue. We believe this differentiated biology may enable IDP-001 to drive meaningful clinical activity with a wider therapeutic window across a range of squamous and selected non-squamous solid tumors. Our goal now is to determine whether IDP-001 can translate that potential into improved outcomes for patients who currently have too few treatment options.”

“InduPro’s induced-proximity platform has opened a window into cell-surface biology by mapping protein neighborhoods overlooked by conventional target-discovery approaches. The team is using those insights as a powerful engine for discovering selective co-target pairs and building a compelling pipeline,” said Sarah Hymowitz, Ph.D., Partner at The Column Group and InduPro Board Chair. “Our ongoing support for InduPro reflects our conviction in the team’s platform, their deep expertise and demonstrated execution, and their strategic agreements with pharma partners to develop more selective and effective medicines.”

Read Also - Form Energy Raises $750M in Series G Funding to Expand its West Virginia Battery Factory